KR20030039143A - Novel benzofuran compound from Suillus granulatus and antioxidative composition comprising it as an active material - Google Patents
Novel benzofuran compound from Suillus granulatus and antioxidative composition comprising it as an active material Download PDFInfo
- Publication number
- KR20030039143A KR20030039143A KR1020010070086A KR20010070086A KR20030039143A KR 20030039143 A KR20030039143 A KR 20030039143A KR 1020010070086 A KR1020010070086 A KR 1020010070086A KR 20010070086 A KR20010070086 A KR 20010070086A KR 20030039143 A KR20030039143 A KR 20030039143A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- benzofuran compound
- concentrating
- extract
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- -1 benzofuran compound Chemical class 0.000 title claims description 19
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title claims description 18
- 241000231258 Suillus granulatus Species 0.000 title abstract 3
- 239000011149 active material Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 5
- 238000004440 column chromatography Methods 0.000 abstract description 4
- 150000001907 coumarones Chemical class 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000000401 methanolic extract Substances 0.000 abstract description 3
- 238000010898 silica gel chromatography Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 4
- 239000002024 ethyl acetate extract Substances 0.000 abstract 2
- 238000007598 dipping method Methods 0.000 abstract 1
- 229940093499 ethyl acetate Drugs 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 abstract 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 abstract 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 229940123973 Oxygen scavenger Drugs 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000013600 Diabetic vascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003808 methanol extraction Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000222562 Suillus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 젖비단그물버섯 유래의 신규한 벤조퓨란계 화합물 및 이를 유효성분으로 함유하는 항산화 조성물에 관한 것이다. 더욱 상세하게는, 본 발명은 젖비단그물버섯으로부터 순수하게 추출분리하여 얻은 항산화활성을 가지는 신규한 벤조퓨란계 화합물 및 이를 유효성분으로 함유하는 항산화 조성물에 관한 것이다.The present invention relates to a novel benzofuran compound derived from lactose net mushroom and an antioxidant composition containing the same as an active ingredient. More specifically, the present invention relates to a novel benzofuran compound having an antioxidant activity obtained by purely extracting and separating lactose net mushrooms and an antioxidant composition containing the same as an active ingredient.
활성산소는 뇌혈관 장애로 인한 뇌졸중, 심근경색, 당뇨병성 혈관장애, 고지혈증, 급성염증, 류마티스 질환, 알콜성 간염, 동맥경화, 발암, 노화등을 비롯한 다양한 질환의 직접 혹은 간접적인 유발원인이 되고 있다. 활성산소 소거물질은 이들 질병을 경감 혹은 예방할 수 있는 것으로 보고되고 있으며 미생물 및 식물체로부터 다양한 활성산소 소거물질이 발견되었고 의약용 혹은 화장품 및 식품 첨가물로 사용되고 있다.Free radicals are a direct or indirect cause of various diseases, including stroke, myocardial infarction, diabetic vascular disorders, hyperlipidemia, acute inflammation, rheumatic diseases, alcoholic hepatitis, arteriosclerosis, carcinogenesis, and aging due to cerebrovascular disorders. have. Active oxygen scavengers have been reported to reduce or prevent these diseases, and various active oxygen scavengers have been found in microorganisms and plants and are used as pharmaceuticals or cosmetics and food additives.
각종 산화반응, 화학약품, 식품, 인체질환 및 방사선 등에 의해 슈퍼옥사이드(superoxide, ·O2), 하이드록실라디칼(hydroxyl radical, ·OH) 및 과산화수소 (H2O2) 등과 같은 반응성이 큰 강한 활성산소와 유리라디칼(free radical)등이 생체내에 생성되면 이들에 의해서 불포화 지방산이 다량 함유된 세포막의 인지질이 산화되어 세포막에 지질 과산화물이 생성되게 된다. 세포막에 지질 과산화물이 축적되게 되면 세포막의 유동성과 기능성이 저하됨으로 세포의 전체적인 기능이 억제되고 세포의 구조도 변화하는 등 조직상에 국소적인 장해가 생기면서 각종 질환이 유발되게 되는 것이다. 따라서 인체내에 반응성이 큰 활성산소와 유리라디칼이 과량으로 축적되게 되면 뇌졸증, 심근경색, 당뇨병성 혈관장애, 고지혈증, 급성염증, 류마티스 질환, 알콜성 간염 등의 간장질환 등 각종 인체 질환을 일으키게 된다. 따라서 강력하면서도 독성이 없는 활성산소 소거물질은 각종 질병의 치료제 개발이나 노화방지용 화장품 첨가제 및 식품첨가제 등으로 매우 유용하게 활용될 것이다. 지금까지 항산화 화합물로는 BHT(butylated hydroxy toluene) 및 BHA(butylated hydroxyanisol) 등과 같은 합성 항산화제가 사용되어 왔으나 이들 BHT나 BHA는 항산화 활성은 우수하나 암 또는 기형을 유발할 수 있는 가능성이 매우 높아 계속적으로 사용할 수 없는 단점이 있었다. 따라서 천연물로부터 새로운 활성산소소거물질을 창출하여 독성이나 부작용이 전혀 없는 항산화제를 개발하는 것이 요구되고 있다.Highly reactive activity such as superoxide (OH 2 ), hydroxyl radical (OH) and hydrogen peroxide (H 2 O 2 ) due to various oxidation reactions, chemicals, food, human diseases and radiation When oxygen and free radicals are generated in vivo, the phospholipids of the cell membrane containing a large amount of unsaturated fatty acids are oxidized, thereby producing lipid peroxides on the cell membrane. Accumulation of lipid peroxides in the cell membrane reduces the fluidity and functionality of the cell membrane, thereby inhibiting the overall function of the cell and changing the structure of the cell. Therefore, if excessive reactive oxygen and free radicals accumulate in the human body, various human diseases such as stroke, myocardial infarction, diabetic vascular disorders, hyperlipidemia, acute inflammation, rheumatic diseases, alcoholic hepatitis, and the like are caused. Therefore, the active oxygen scavenger that is powerful but not toxic will be very useful as a therapeutic agent for various diseases or as an anti-aging cosmetic additive and food additive. Until now, synthetic antioxidants such as butylated hydroxy toluene (BHT) and butylated hydroxyanisol (BHA) have been used as antioxidant compounds. However, these BHT and BHA have excellent antioxidant activity but are highly likely to cause cancer or malformation. There was a disadvantage. Therefore, it is required to develop an antioxidant that has no toxicity or side effects by creating a new active oxygen scavenger from natural products.
본 발명자들은 상기와 같은 점을 감안하여 각종 버섯 및 약용식물을 채집하여 조사하던 중 젖비단그물버섯을 메탄올 추출한후 크로마토그래피를 이용하여 순수 분리정제하여 신규한 벤조퓨란계 화합물을 얻고 이의 화학구조 및 물리화학적 특성을 규명한 뒤 디피피에이치 라디칼 소거활성을 조사하여 항산화능력을 평가하고 이를 각종 화장품 제형에 활용함으로써 본 발명을 완성하였다.In view of the above, the present inventors collected and investigated various mushrooms and medicinal plants, and obtained pure benzofuran-based compounds by methanol extraction of lactose net mushrooms, and then chromatographic extraction to obtain novel benzofuran compounds. After physicochemical characteristics were investigated, the present invention was completed by evaluating the antioxidant activity by investigating DPH radical scavenging activity and using it in various cosmetic formulations.
따라서, 본 발명의 목적은 젖비단그물버섯으로부터 순수하게 분리정제하여 얻은 항산화활성을 가지는 신규한 벤조퓨란계 화합물을 제공함에 있다. 본 발명의 다른 목적은 젖비단그물버섯으로부터 순수하게 분리정제하여 얻은 항산화활성을 가지는 신규한 벤조퓨란계 화합물을 유효성분으로 함유하는 항산화 조성물을 제공함에 있다.Accordingly, an object of the present invention is to provide a novel benzofuran compound having antioxidant activity obtained by purely purified from lactose net mushroom. Another object of the present invention is to provide an antioxidant composition containing a novel benzofuran compound having an antioxidant activity obtained by purely separating and purifying from lactose net mushroom.
본 발명의 상기 목적은 젖비단그물버섯을 메탄올 추출한후 크로마토그래피를 이용하여 순수 분리정제하여 신규한 벤조퓨란계 화합물을 얻고 이의 화학구조 및 물리화학적 특성을 규명한 뒤 디피피에이치 라디칼 소거활성을 조사하여 항산화능력을 평가하고 이를 각종 화장품 제형에 활용함으로써 달성하였다.The object of the present invention is to extract novel benzofuran compound by methanol extraction of lactose net mushrooms and then purified by chromatography to investigate the chemical structure and physicochemical properties of the python H radical scavenging activity This was achieved by evaluating antioxidant capacity and using it in various cosmetic formulations.
이하 본 발명의 구성을 설명한다.Hereinafter, the configuration of the present invention.
본 발명은 젖비단그물버섯을 마쇄한후 메탄올로 추출하고 크로마토그래피를 이용하여 신규한 벤조퓨란계 화합물을 순수하게 분리정제하는 단계; 상기 단계에서 얻은 화합물의 화학구조 및 물리화학적 특성을 조사하는 단계; 상기 단계의 화합물을 각종 화장품 제형에 활용하는 단계로 구성된다.The present invention comprises the steps of pulverizing lactose net mushrooms and extracting with methanol, and purified and purified the novel benzofuran compound purely using chromatography; Examining the chemical structure and physicochemical properties of the compound obtained in the step; Comprising the step of using the compound of the various cosmetic formulations.
본 발명에 따른 신규한 벤조퓨란계 화합물 슐러신은 하기 화학식을 갖는다.The novel benzofuran compound Schulsine according to the present invention has the following formula.
본 발명에 따른 신규한 벤조퓨란계 화합물의 물리화학적 특성은 다음과 같다.Physical and chemical properties of the novel benzofuran compound according to the present invention are as follows.
성상: 황색의 분말Appearance: Yellow Powder
분자량: 370Molecular Weight: 370
분자식: C19H14O8 Molecular Formula: C 19 H 14 O 8
선광도: [α]D+ 4 (c1.0, MeOH)Radiance: [α] D + 4 ( c 1.0, MeOH)
질량분선 스펙트럼 : HREIMSm/z370.0705 [M]+ Mass Segmentation Spectrum: HREIMS m / z 370.0705 [M] +
EIMSm/z370 [M]+ EIMS m / z 370 [M] +
자외선흡수스펙트럼 : UVλmax (MeOH)(logε)UV absorption spectrum: UV λ max (MeOH) (log ε )
223 (sh) (3.56), 261 (3.21), 311 (sh) (3.30),223 (sh) (3.56), 261 (3.21), 311 (sh) (3.30),
348 (3.42) nm348 (3.42) nm
적외선스펙트럼 : IR (KBr)νmaxInfrared spectrum: IR (KBr) ν max
3412, 2924, 2852, 1728 (sh), 1703, 16113412, 2924, 2852, 1728 (sh), 1703, 1611
1523, 1490, 1439, 1386, 1284, 1218 cm-1 1523, 1490, 1439, 1386, 1284, 1218 cm -1
수소핵자기공명스펙트럼 : ppm (600 MHz)Hydrogen Magnetic Resonance Spectrum: ppm (600 MHz)
1H NMR (CD3OD) : 7.64 (1H, d,J= 2.0 Hz, H-2), 7.42 (1H, dd,J= 8.8, 2.0 Hz, H-6), 6.81 (1H, dd,J= 2.4, 1.0 Hz, H-8), 6.79 (1H, d,J= 8.8 Hz, H-5), 6.68 (1H, d,J= 8.8 Hz, H-5), 6.64(1H, ddd,J= 8.8, 2.4, 1.0 Hz, H-6), 4.15 (1H, br s, H-8b), 3.72 (3H, s, OCH 3);1H NMR (acetone-d 6 ) d 9.17 (1H, s, OH), 8.34 (2H, s, OH), 8.02 (1H, s, OH), 7.67 (1H, d,J= 2.2 Hz, H-2), 7.52 (1H, dd,J= 8.4, 2.2 Hz, H-6), 6.90 (1H, d,J= 8.4 Hz, H-5), 6.84 (1H, m, H-8), 6.69 (1H, m, H-5), 6.69 (1H, m, H-6), 4.27 (1H, br s, H-8b), 3.71 (3H, s, OCH 3) 1 H NMR (CD 3 OD): 7.64 (1H, d, J = 2.0 Hz, H-2), 7.42 (1H, dd, J = 8.8, 2.0 Hz, H-6), 6.81 (1H, dd, J = 2.4, 1.0 Hz, H-8), 6.79 (1H, d, J = 8.8 Hz, H-5), 6.68 (1H, d, J = 8.8 Hz, H-5), 6.64 (1H, ddd, J = 8.8, 2.4, 1.0 Hz, H-6), 4.15 (1H, br s, H-8b), 3.72 (3H, s, OC H 3 ); 1 H NMR (acetone- d 6 ) d 9.17 (1H, s, O H ), 8.34 (2H, s, O H ), 8.02 (1H, s, O H ), 7.67 (1H, d, J = 2.2 Hz , H-2), 7.52 (1H, dd, J = 8.4, 2.2 Hz, H-6), 6.90 (1H, d, J = 8.4 Hz, H-5), 6.84 (1H, m, H-8) , 6.69 (1H, m, H-5), 6.69 (1H, m, H-6), 4.27 (1H, br s, H-8b), 3.71 (3H, s, OC H 3 )
탄소핵자기공명스펙트럼 : ppm (150 MHz)Carbon Magnetic Resonance Spectrum: ppm (150 MHz)
13C NMR (CD3OD) : 197.8 (C-1), 173.5 (COOCH3), 153.8 (C-4a), 153.4 (C-7), 151.0 (C-2), 148.3 (C-4), 146.2 (C-3), 137.2 (C-3), 125.3 (C-1), 123.9(C-8a), 122.8 (C-6), 117.4 (C-6), 117.1 (C-2), 116.2 (C-5), 112.2 (C-8), 111.7 (C-5), 91.9 (C-3a), 56.9 (C-8b), 53.7 (COOCH3) 13 C NMR (CD 3 OD) : 197.8 (C-1), 173.5 (C OOCH 3), 153.8 (C-4a), 153.4 (C-7), 151.0 (C-2), 148.3 (C-4) , 146.2 (C-3), 137.2 (C-3), 125.3 (C-1), 123.9 (C-8a), 122.8 (C-6), 117.4 (C-6), 117.1 (C-2), 116.2 (C-5), 112.2 (C-8), 111.7 (C-5), 91.9 (C-3a), 56.9 (C-8b), 53.7 (COO C H 3 )
상기와 같은 물리화학적 특성 및 핵자기공명 스펙트럼의 해석으로부터 본 발명에 따른 화합물 슐러신은 신규한 벤조퓨란계 화합물로 규명되었다.From the analysis of the above physicochemical properties and nuclear magnetic resonance spectra, the compound Schullin according to the present invention was identified as a novel benzofuran compound.
본 발명에 따른 벤조퓨란계 화합물은 그물버섯(Suillus) 속에 속하는 버섯자실체 및 균사체 배양액으로부터 유기용매(알코올, 에테르, 아세톤등)에 의하여 추출, 초산에틸과 물의 분배, 컬럼크로마토그래피 등, 버섯성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합하여 용이하게 얻을 수가 있다. 조추출물은 필요에 따라서 상법에 따라서 더욱 정제할 수 있다.The benzofuran compound according to the present invention is extracted from an organic solvent (alcohol, ether, acetone, etc.) from mushroom fruit bodies and mycelium cultures belonging to the genus Mushroom ( Suillus ), distribution of ethyl acetate and water, column chromatography, etc. Known methods used for separation extraction can be easily obtained alone or in combination as appropriate. The crude extract can be further purified according to a commercial method as needed.
본 발명에서 사용하는 크로마토그래피에는 실리카겔 컬럼 크로마토그래피 (silica gel culumn chromatography), 엘에이취-20 컬럼 크로마토그래피(LH-20 culumn chromatography), 박층크로마토그래피(TLC; thin layer chromatography) 및 고성능 액체 크로마토그래피(high performance liquid chromatography) 등이 이용될 수 있다.Chromatography used in the present invention includes silica gel column chromatography, silica-20 column chromatography, thin layer chromatography (TLC) and high performance liquid chromatography (TLC). high performance liquid chromatography) and the like.
본 발명에 따른 신규한 벤조퓨란계 화합물 슐러신은 디피피에이치 라디칼을 소거하는 작용을 가지고 있으며 다른 디피피에이치 라디컬 소거 물질보다도 세포독성이 낮아서 생체내 항산화제로 활용할 수 있다.The novel benzofuran compound Schulsine according to the present invention has a function of scavenging DPP radicals and is lower in cytotoxicity than other DPH radical scavenging substances and thus can be utilized as an antioxidant in vivo.
본 발명에 따른 신규한 벤조퓨란계 화합물 슐러신은 탁월한 디피피에이치 라디칼 소거활성을 나타낼뿐만 아니라 안정성도 높아 항산화제로 식품, 음료 및 화장품등의 첨가제로 이용할 수 있다. 또한 생체내 항산화활성을 이용하여 각종 의약품으로 사용할 수도 있다.The novel benzofuran compound Schulsine according to the present invention not only shows excellent DPH radical scavenging activity but also has high stability and can be used as an additive for food, beverage and cosmetics as an antioxidant. In addition, it can also be used in various medicines by using the antioxidant activity in vivo.
의약품에 적용할 경우에는 본 발명에 따른 화합물 슐러신을 유효성분으로하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구투여제 혹은 비경구 투여제로 제제화할 수 있다.When applied to pharmaceuticals can be formulated as an oral or parenteral dosage form in the form of a solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier with the compound Schulsin according to the present invention as an active ingredient.
경구투여을 위한 제재로서는 정제(錠劑), 환제(丸劑), 과립제(顆粒劑), 연·경 캡슐제, 산제, 세립제, 분제, 유탁제(乳濁濟), 시럽제, 펠렛제 등을 들 수 있다. 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제(坐劑) 등을 들 수가 있다. 본 발명의 유효성분을 제제화하기 위하여는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of preparations for oral administration include tablets, pills, granules, soft and hard capsules, powders, fine granules, powders, emulsions, syrups and pellets. have. Preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspensions, and other commonly used auxiliaries can be suitably used.
이하 본 발명의 구체적인 방법을 실시예를 들어 단계별로 설명하고자 하지만 본 발명의 권리범위는 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the specific method of the present invention will be described step by step with reference to Examples, but the scope of the present invention is not limited only to these Examples.
실시예 1 : 벤조퓨란계 화합물 슐러신의 분리 및 정제Example 1 Isolation and Purification of the Benzofuran Compound Schleusin
젖비단 그물버섯 자실체를 메탄올에 3일간 침지하여 실온에서 추출하였다. 상기 메탄올 추출물을 감압농축한 후 남은 잔여물을 에틸아세테이트로 추출하고 상기 추출물을 감압농축하여 CHCl3:MeOH를 전개용매로 하여 실리카겔 컬럼 크로마토그래피를 실시하였다. 위에서 얻은 활성분획을 농축한 후 CHCl3:MeOH(2:1)을 전개용매로 하여 세파덱스 엘에이치-20 컬럼 크로마토그래피(Sephadex LH-20 column chromatography)를 수행하여 신규 벤조 퓨란계 화합물 슐러신 15㎎을 분리하였다.Lactose silk mushroom fruiting bodies were immersed in methanol for 3 days and extracted at room temperature. The methanol extract was concentrated under reduced pressure, and the remaining residue was extracted with ethyl acetate, and the extract was concentrated under reduced pressure, and subjected to silica gel column chromatography using CHCl 3 : MeOH as a developing solvent. After concentrating the active fraction obtained above, Sepadex LH-20 column chromatography was performed using CHCl 3 : MeOH (2: 1) as a developing solvent. Was separated.
실시예 2 : 벤조퓨란계 화합물 슐러신의 물리화학적 특성 및 화학구조 분석Example 2 Analysis of Physicochemical Properties and Chemical Structure of Benzofuran Compound Schulsin
상기와 같이 얻은 화합물 슐러신은 황색의 분말이었으며 EI-mass 측정 결과 분자량이 370임을 알 수 있었다. 고분해능 EI-mass 측정 결과 상기 화합물의 분자식이 C19H14O8임을 결정할 수 있었다. UV 스펙트럼을 측정한 결과 223, 261, 311, 348 nm에서 극대흡수피크를 나타내었으며 IR 스펙트럼을 측정한 결과 3412 cm-1에서 히드록시기(hydroxyl group), 1728 및 1703 cm-1에서 카보닐기(carbonyl group)에 기인하는 밴드들이 관찰되었다. 선광도는 각각 +4°이었다.Compound Schlussin obtained as described above was a yellow powder and the molecular weight was 370 by EI-mass measurement. As a result of high resolution EI-mass measurement, the molecular formula of the compound was determined to be C 19 H 14 O 8 . UV spectra showed maximum absorption peaks at 223, 261, 311, and 348 nm, and IR spectra showed hydroxyl groups at 3412 cm -1 and carbonyl groups at 1728 and 1703 cm -1 . ) Bands were observed. The fluorescence was + 4 ° each.
실시예 3 : 디피피에이치(DPPH) 라디칼 소거 활성 조사Example 3 Investigation of DPPH Radical Scavenging Activity
슐러신 100㎍을 20㎕의 메탄올에 녹인후 150μM의 디피피에이치 에탄올 용액 980㎕에 부가하였다. 볼텍스를 이용하여 상기 용액을 잘 섞은후 실온에서 20분간 방치하고 517 nm에서 흡광도를 측정하였다. 대조구로서 동일농도인 100 ㎍/㎖의 BHA(butylated hydroxyanisole)와 비타민 E를 사용하였다. 그 결과 슐러신 30%, BHA 76%, 비타민 E 73%의 디피피에이치(DPPH) 라디칼 소거 활성을 나타내었다. 비록 슐러신이 대조구보다 낮은 활성을 나타내었으나 본 화합물은 식용버섯으로부터 분리되어 독성이 없으며 또한 새로운 골격의 항산화제를 제공할 수 있는 장점이 있다.100 μg of Schusin was dissolved in 20 μl of methanol and added to 980 μl of 150 μM DPH ethanol solution. The solution was mixed well using a vortex and left at room temperature for 20 minutes, and the absorbance was measured at 517 nm. As a control, the same concentration of 100 ㎍ / ㎖ BHA (butylated hydroxyanisole) and vitamin E was used. As a result, it showed a DPPH radical scavenging activity of 30% of sucrose, 76% of BHA, and 73% of vitamin E. Although Schulsine showed lower activity than the control, the compound is isolated from edible mushrooms and is not toxic and has the advantage of providing a new skeleton antioxidant.
실시예 4 : 젖비단그물버섯 추출물을 함유하는 화장품 제조Example 4 Preparation of Cosmetics Containing Lactobacillus Extract
상기 실시예 1에서 얻은 젖비단그물버섯 추출물을 일정 중량% 첨가하여 일반적인 종래 공정에 따라 화장수, 화장용 크림 및 팩제를 제조하였다. 상기 각 제형의 배합성분 및 각 배합성분의 중량%를 하기 표 1, 2 및 3에 나타내었다.By adding a certain weight% lactose net mushroom extract obtained in Example 1 to prepare a lotion, cosmetic cream and pack according to a conventional conventional process. The blending ingredients of each formulation and the weight percentage of each blending component are shown in Tables 1, 2, and 3 below.
이상, 상기 실시예를 통하여 설명한 바와 같이 본 발명의 화합물 슐러신은 항산화활성을 가질뿐만 아니라 식용버섯인 젖비단그물버섯으로부터 추출분리하여 세포 독성이 없어 의약품, 화장품 및 식품산업상 매우 유용한 발명인 것이다.As described above, the compound Schulsine of the present invention, as described through the above examples, has an antioxidant activity and extracts and isolates from edible mushrooms, which are edible mushrooms.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020010070086A KR20030039143A (en) | 2001-11-12 | 2001-11-12 | Novel benzofuran compound from Suillus granulatus and antioxidative composition comprising it as an active material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020010070086A KR20030039143A (en) | 2001-11-12 | 2001-11-12 | Novel benzofuran compound from Suillus granulatus and antioxidative composition comprising it as an active material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030039143A true KR20030039143A (en) | 2003-05-17 |
Family
ID=29568946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020010070086A Ceased KR20030039143A (en) | 2001-11-12 | 2001-11-12 | Novel benzofuran compound from Suillus granulatus and antioxidative composition comprising it as an active material |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20030039143A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07215852A (en) * | 1994-01-31 | 1995-08-15 | Kobe Steel Ltd | Immunosuppressant |
-
2001
- 2001-11-12 KR KR1020010070086A patent/KR20030039143A/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07215852A (en) * | 1994-01-31 | 1995-08-15 | Kobe Steel Ltd | Immunosuppressant |
Non-Patent Citations (2)
| Title |
|---|
| J Nat Prod. 2001 Sep;64(9):1230-1 * |
| 한국미생물생명공학회지. Vol. 29, No. 3, 149-154, 2001 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nessa et al. | Free radical-scavenging activity of organic extracts and of pure flavonoids of Blumea balsamifera DC leaves | |
| Jung et al. | Antioxidant flavonoids and chlorogenic acid from the leaves of Eriobotrya japonica | |
| Gontijo et al. | Leishmanicidal, antiproteolytic and antioxidant evaluation of natural biflavonoids isolated from Garcinia brasiliensis and their semisynthetic derivatives | |
| US20240270779A1 (en) | Novel phenylpropanoid compound | |
| EP4321518A1 (en) | Novel polyphenol compound | |
| KR100833121B1 (en) | Novel compounds with active oxygen scavenging activity, preparation method thereof and composition comprising the same | |
| JP6923100B1 (en) | New isoflavone compound | |
| KR100466031B1 (en) | Novel antioxidative compounds from Daldinia concentrica and antioxidative composition comprising it as an active material | |
| KR20030039143A (en) | Novel benzofuran compound from Suillus granulatus and antioxidative composition comprising it as an active material | |
| KR100330137B1 (en) | Novel triterpene-series chemical compound capable of inhibiting lipid-peroxidation and process for preparation thereof | |
| KR101309114B1 (en) | Isoindolinone affiliated antioxidation compound isolated from Daldinia concentrica and isolation method thereof | |
| KR20010008772A (en) | Hispidin-series chemical compound capable of removing active oxygen and process for prepration thereof | |
| JP5567499B2 (en) | Novel substances isolated from orchidaceae plants, extracts containing them, antioxidants, antibacterial agents, anticancer agents and anti-inflammatory agents | |
| KR101054943B1 (en) | Phenolic Compounds with Antioxidant Activity from Coding Tea Extract and Functional Foods Comprising the Same as Active Ingredients | |
| KR20180013666A (en) | Antioxidant composition comprising uldavioside A | |
| KR20020013237A (en) | Chamchi (Aster scaber) extracts and compounds with hypocholesterolemic, antioxidative and antiviral activities | |
| KR102711584B1 (en) | Novel anti-inflammatory compound and pharmaceutical composition for preventing or treating inflammatory diseases comprising the same as an active ingredient | |
| US20250134799A1 (en) | Composition containing nero di troia pomace extract | |
| KR100811614B1 (en) | Antioxidant Activity Extract from Pleurotus eryngii Mycelia Culture, Compound with Novel Oxygen Oxygen Ability Isolated from It, and Manufacturing Method Thereof | |
| KR100882194B1 (en) | Compound isolated from sesame extract with antihyperlipidemic, antioxidant and antiviral activity | |
| KR20010057776A (en) | Skin whitening agent | |
| KR100371085B1 (en) | New ellagitannin glycosides | |
| Ansari et al. | Isolation, Structure Elucidation, and Antioxidant Activity of Chemical Constituents from Artocarpus lakoocha Fruits | |
| JP4182230B2 (en) | Novel glycoside, process for producing the same and composition | |
| KR20250007830A (en) | Antioxidant compounds derived from Sargassum macrocarpum and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20011112 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040130 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20040430 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040130 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |